Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE-C-Plus: Camrelizumab, Famitinib, and Nab-paclitaxel in TNBC
NCT04129996Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib and camrelizumab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 53 months. Status: unknown.
02
Drugs
famitinibcamrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04129996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129996.